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Further evidence of the beneﬁts associated with antiviral treatment
in kidney allograft recipients with chronic hepatitis B virus
infection
To the Editor:
We read with interest about the recent study on the beneﬁts
associated with antiviral treatment in kidney allograft recipients
with chronic hepatitis B virus (HBV) infection by Cosconea et al.
[1]. We highly appreciate the authors’ results achieved with a
speciﬁc group of patients with HBV. The authors acknowledged
that there is still a lack of data on HBV kidney recipients’ long-
term survival. Therefore, we would like to present our results
supporting the French group results. The immunosuppressive
treatment in patients with chronic HBV infection leads to the loss
of immune control of viraemia, hepatitis reactivation, ﬁbrosis
progression and hepatocellular carcinoma (HCC) occurrence
[2,3]. In 1999, Mathurin et al. precisely described the negative
impact of HBV on the survival of untreated patients after kidney
transplantation (RTx) [4].
We retrospectively assessed 30 HBsAg-positive kidney allo-
graft recipients who started antiviral treatment of HBV with
nucleos(t)ide analogues (NUCs) between 1998 and 2007. The
underlying renal disease was chronic glomerulonephritis in 17
patients, chronic interstitial nephritis in 7, polycystic kidney in
2, hypertensive nephropathy in 1 and unknown in 3 patients.
Seven patients suffered from type 2 diabetes, 7 had BMI >30
and none reported the consumption of more than 20 g of alcohol
per day. All the patients had negative serology for hepatitis C and
HIV. All the patients received the standard immunosuppressive
protocol used at the centre at the time of transplantation: two
patients were on an azathioprine and prednisone regimen, 21
patients were on a cyclosporine regimen (together with predni-
sone and azathioprine or mycophenolate mofetil) and 7 patients
were on immunosuppressive combination of tacrolimus, myco-
phenolate mofetil and prednisone. At the time of transplantation,
all the patients were HBsAg positive with normal ALT values and
normal synthetic liver function. The negative viraemia had to be
documented only in the patients transplanted after 1999. The
liver biopsies before RTx were performed by the referring centres
and only patients with mild inﬂammatory activity and without
cirrhosis were allowed. The antiviral treatment was started after
RTx in all patients who presented hepatitis reactivation, as soon
as the NUCs became available. All had detectable viraemia before
treatment, 16 of them were HBeAg positive and 14 HBeAg nega-
tive. A subsequent liver biopsy was performed in 23/30 patients
before treatment (2–6 weeks before starting NUCs), 16 had ﬁbro-
sis F0–F2 and 7 F3–F4 according to the Metavir score. The treat-
ment was initiated with lamivudine (LAM) monotherapy in 28
patients and adefovir (ADV) was added for the patients with
reappearance of viraemia. If the LAM + ADV combination had
not resulted in undetectable viraemia, then ADV was switched
to tenofovir (TDF). Entecavir (ETV) was started in 2 patients
and in 1 of them ETV was switched to TDF due to pregnancy.
The antiviral doses were adjusted to kidney function. HBV DNA
at the end of the follow-up (June 2012) was assessed using the
Cobas Ampliprep/TaqMan method (lower limit of detec-
tion = 20 IU/ml). HCC screening was performed by ultrasound.
The patients and kidney grafts survival was assessed using the
Kaplan–Meier method.
The average treatment duration was 108 months (30–156).
Five patients died with no relation to the liver disease (1 myocar-
dial infarction, 2 strokes, 1 sepsis and 1 skin tumour). Twenty-ﬁve
patients are still living and continue treatment and 24 have unde-
tectable viraemia. Eight patients remain on LAM monotherapy, 1
on ETV, 1 on TDF, 6 on LAM + ADV combination and 9 LAM + TDF.
9/16 HBeAg-positive patients achieved seroconversion. Viraemia
reappeared on LAM monotherapy in 6/9 patients who achieved
HBeAg seroconversion and ADV or TDF was added. In 9 patients,
renal graft failure occurred due to chronic allograft nephropathy
(2–12 years after NUCs treatment initiation, 4–20 years after
RTx). No renal toxicities related to ADV/TDVwere observed. Serum
creatinine (225, 77–289 lmol/L, resp. 210, 73–261 lmol/L,
p = 0.055, resp. p = 0,363) and serum phosphate levels (1.06,
0.90–1.42 mmol/L, resp. 1.08, 0–1.45 mmol/L, p = 0.530, resp.
0.674), after 1 and 3 years of therapy, did not differ signiﬁcantly
from the average values before starting ADV/TDF (168, 94–271
lmol/L, resp. 1.20, 0.83–2.62 mmol/L, Wilcoxon non-parametric
test). On treatment, 2 patients underwent further RTx (1 with
liver). 18/25 living patients have a well-functioning kidney allo-
graft, with the average creatinine clearance of 48.6 ml/min at the
end of the follow-up; and the 10-year graft survival in our cohort
did not differ from the overall graft survival at our centre. One
patientwith cirrhosis at biopsy before treatment experienced liver
decompensation, when LAM resistance emerged, and he under-
went liver and kidney transplantation. At present, the function of
both grafts is excellent after 5 years and he is being treated with
LAM + TDF and hepatitis B immunoglobulin. Another patient with
liver cirrhosis had also liver dysfunction after the emergence of
LAM resistance. His liver function improved on LAM + ADV, but
seven years later he presented with ascites and kidney graft fail-
ure, and he is currently awaiting liver and kidney transplant. None
of our patients was diagnosed with HCC. The results, including
5- and 10-year patients and grafts survival, are summarised in
Table 1 and Fig. 1.
The patients and grafts survival in our cohort is substantially
better than in the cohort described by Ahn et al. [5], but is slightly
worse than in the Cosconea et al. cohort [1]. Ahn et al. adminis-
tered only LAM and ADV; after 5 years, they had only 58.3%
patients with undetectable viraemia. In our cohort, 12
LAM + ADV patients who had detectable viraemia were switched
to LAM + TDV. The excellent results by Cosconea et al. have been
achieved thanks to early availability of the third generation antiv-
irals. Our results could be inﬂuenced by delayed availability of
the antivirals in the Czech Republic (LAM 1998, ADV 2005, ETV
and TDF 2008). The statement is supported by the fact that liver
decompensation occurred in 2 patients with ﬂare-up due to LAM
resistance in whom ADV was initiated more than 1 year after
viraemia reappearance. Both patients were enlisted for combined
liver and kidney transplantation according to our centre
guidelines (liver dysfunction due to cirrhosis corresponding to
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Child-Pugh B class in a patient with creatinine clearance < 30 ml/
min or on maintenance hemodialysis).
The effect of antiviral therapy was signiﬁcant despite the fact
that in our historical cohort, the antiviral treatment was initiated
with delay after RTx when HBV reactivated. Since 2008, all NUC-
naïve, HBsAg positive patients with undetectable viraemia have
received pre-emptive therapy with ETV from the day of trans-
plant. Patients with pre-transplant detectable viraemia continue
the treatment started on maintenance hemodialysis (ETV in
NUC-naïve, TDF in LAM-experienced patients). The viraemia is
regularly assessed every 3 months.
HCC absence in our cohort can be explained by a lower rate of
F3–F4 patients (7/30 vs. 15/42 or 23.3% vs. 33.3%) and by the
small cohort size. We would like to emphasise the necessity of
regular screening [6].
We conclude that the results of our cohort substantiate
the beneﬁcial effect of antiviral treatment in HBsAg+ kidney
graft recipients. The achievement of a long-term undetectable
viraemia is the goal of the therapy, which should be initiated
with third generation antivirals according to present guide-
lines [7].
Conﬂict of interest
All the authors declare that they do not have anything to disclose
regarding funding or conﬂict of interests with respect to this
manuscript.
Table 1. Comparison of characteristics and results of our group with the group studied by Cosconea et al.
Cosconea et al., [1] Sperl et al., (current study)
Age (yr), median (range) 54 (22-78) 54.5 (39-79)
Sex (male/female) 33/9 22/8
Follow-up post-RTx (yr), median (range) 15.4 (1-39) 13 (4-33) 
Year of transplantation, (median) 1994 1998
Duration of dialysis (yr), median 6.8 2.0
Treatment at the end of follow-up
Monotherapy
Combined therapy
Lamivudine-resistant 
18/42 (42.8%)
24/42 (57.2%)
19/42 (45%)
10/30 (33.3%)
17/30 (56.7%)
18/30 (60.0%)
Exposed to drug
Liver fibrosis before NUCs
Lamivudine
Entecavir
Adefovir
Tenofovir
Total lines of treatment
37/42 (88.0%)
15/42 (35.7%)
24/42 (57.2%)
10/42 (23.8%)
90
28/30 (94.0%)
2/30 (6.0%)
18/30 (60.0%)
12/30 (40.0%)
60
F0-F2 (mild)
F3-F4 (advanced)
Biopsy not done
18
15
9/42
16
7
7/30
HBV DNA before NUCs
Undetectable
Detectable
Not available
1/42 (2.4%)
30/42 (71.4%)
11/42 (26.2%)
0
30/30 (100.0%)
0
HBV DNA at the end of follow-up
Undetectable
Detectable
Not available
39/42 (92.9%)
3/42 (7.1%)
0
29/30 (96.7%)
1/30 (3.3%)
0
Patient survival (%)
5 yr
10 yr
100
97.6
100
91.9
Graft survival (%)
5 yr
10 yr 
100
97.6
96.7
86.3
RTx, kidney transplantation; NUCs, nucleos(t)ide analogues.
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Fig. 1. Kaplan Meier survival curves for patients and kidney grafts in HBsAG
positive kidney graft recipients.
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Reply to: ‘‘Further evidence of the beneﬁts associated
with antiviral treatment in kidney allograft recipients
with chronic hepatitis B virus infection’’
To the Editor:
We read the interesting results of Sperl et al. [1], reporting the
beneﬁts associated with analogues treatment of HBV-infected
kidney recipients (KR), which corroborate our previous ﬁndings
[2]. A signiﬁcant increase in graft and patient survival was
observed in both our studies, by comparison with series where
analogues were either not available [3,4] or less potent, with viral
resistance concerns [5].
These results are in concordance with the recent updated
european guidelines [6] which recommend HBV screening for
all patients with end-stage renal disease, candidates to renal
transplantation, and analogue as pre-emptive treatment prior
to transplantation, to reduce the risks of HBV reactivation, cirrho-
sis and hepatocellular carcinoma (HCC).
In our study, HCC was responsible for mortality in half of the
cases despite an efﬁcient viral suppression in patients with cir-
rhosis, but with less advanced ﬁbrosis (Metavir F2). This evi-
dences the need of regular ultrasound assessment for HCC early
detection, even if a complete viral suppression is fully achieved.
We speculate that in the future, the use of potent oral antivi-
rals, which do not enhance the risk of graft rejection in hepatitis C
virus (HCV)-infected kidney transplant recipients, will result in
the same beneﬁt, given the harmful impact of HCV infection of
the liver (cirrhosis and HCC), but also of the renal allograft (de
novo glomerulonephritis), on morbidity and mortality.
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